Cutia Therapeutics
HKEX:2487
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cutia Therapeutics
Long-Term Debt
Cutia Therapeutics
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cutia Therapeutics
HKEX:2487
|
Long-Term Debt
¥95.3m
|
CAGR 3-Years
-65%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Long-Term Debt
¥1.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Long-Term Debt
¥2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Long-Term Debt
¥751.9m
|
CAGR 3-Years
93%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Long-Term Debt
¥4B
|
CAGR 3-Years
41%
|
CAGR 5-Years
85%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Long-Term Debt
¥5.5m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cutia Therapeutics
Glance View
Cutia Therapeutics is a holding company that engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai and currently employs 175 full-time employees. The company went IPO on 2023-06-12. The firm is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The firm is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The firm conducts its businesses in the domestic market and overseas markets.
See Also
What is Cutia Therapeutics's Long-Term Debt?
Long-Term Debt
95.3m
CNY
Based on the financial report for Dec 31, 2024, Cutia Therapeutics's Long-Term Debt amounts to 95.3m CNY.
What is Cutia Therapeutics's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
-65%
Over the last year, the Long-Term Debt growth was -7%. The average annual Long-Term Debt growth rates for Cutia Therapeutics have been -65% over the past three years .
